Jeffrey Leyton PhD

Dr. Leyton is a leading scientist, technologist, explorer, and communicator in the field of antibody-based medicines. His work to reinvent how we explore intracellular access for antibodies while retaining phenotype specificity for target cells/tissues has made headlines around the world, merging technology innovation and commercialization in order to make actionable progress to benefit patients. His projects range from an effort to map new intracellular transport routes that increase the cellular accumulation of delivered therapeutic payloads for a class of medicines known as antibody-drug conjugates, to expeditions to address a major chasm in pharmaceutics, drugging undruggable disease-associated intracellular targets, to his most recent efforts to redefine molecular imaging for cancer so doctors can make more informed decisions for patient management and therapeutic action. Jeff is a Universite de Sherbrooke Associate Professor, a Sherbrooke Medical Center research scientist, and a human interested in curiosity and introspection.